Anticholinergic medications for the treatment of chronic obstructive pulmonary disease

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Two inhaled anticholinergic agents, ipratropium bromide (Atrovent) and tiotropium bromide (Spiriva), are approved for symptomatic treatment of chronic obstructive pulmonary disease in the U.S. Both agents comply with the Montreal Protocol: ipratropium is now available in a metered-dose inhaler without chlorofluorocarbons, and tiotropium is provided as a dry-powder inhaler. On the basis of controlled clinical studies of up to one year's duration, scheduled maintenance therapy with tiotropium, administered once daily, was found to be more effective than ipratropium given four times daily in producing bronchodilation, reducing dyspnea, improving health status, and lowering the frequency of disease exacerbation.

Original languageEnglish (US)
Pages (from-to)150-159
Number of pages10
JournalP and T
Volume32
Issue number3
StatePublished - Mar 1 2007

Fingerprint

Ipratropium
Cholinergic Antagonists
Chronic Obstructive Pulmonary Disease
Chlorofluorocarbons
Dry Powder Inhalers
Metered Dose Inhalers
Dyspnea
Health Status
Disease Progression
Tiotropium Bromide

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Anticholinergic medications for the treatment of chronic obstructive pulmonary disease. / Knoell, Daren L.

In: P and T, Vol. 32, No. 3, 01.03.2007, p. 150-159.

Research output: Contribution to journalReview article

@article{1cc644ea410843ea83bf88a0dfd229f2,
title = "Anticholinergic medications for the treatment of chronic obstructive pulmonary disease",
abstract = "Two inhaled anticholinergic agents, ipratropium bromide (Atrovent) and tiotropium bromide (Spiriva), are approved for symptomatic treatment of chronic obstructive pulmonary disease in the U.S. Both agents comply with the Montreal Protocol: ipratropium is now available in a metered-dose inhaler without chlorofluorocarbons, and tiotropium is provided as a dry-powder inhaler. On the basis of controlled clinical studies of up to one year's duration, scheduled maintenance therapy with tiotropium, administered once daily, was found to be more effective than ipratropium given four times daily in producing bronchodilation, reducing dyspnea, improving health status, and lowering the frequency of disease exacerbation.",
author = "Knoell, {Daren L.}",
year = "2007",
month = "3",
day = "1",
language = "English (US)",
volume = "32",
pages = "150--159",
journal = "P and T",
issn = "1052-1372",
publisher = "MediMedia USA Inc.",
number = "3",

}

TY - JOUR

T1 - Anticholinergic medications for the treatment of chronic obstructive pulmonary disease

AU - Knoell, Daren L.

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Two inhaled anticholinergic agents, ipratropium bromide (Atrovent) and tiotropium bromide (Spiriva), are approved for symptomatic treatment of chronic obstructive pulmonary disease in the U.S. Both agents comply with the Montreal Protocol: ipratropium is now available in a metered-dose inhaler without chlorofluorocarbons, and tiotropium is provided as a dry-powder inhaler. On the basis of controlled clinical studies of up to one year's duration, scheduled maintenance therapy with tiotropium, administered once daily, was found to be more effective than ipratropium given four times daily in producing bronchodilation, reducing dyspnea, improving health status, and lowering the frequency of disease exacerbation.

AB - Two inhaled anticholinergic agents, ipratropium bromide (Atrovent) and tiotropium bromide (Spiriva), are approved for symptomatic treatment of chronic obstructive pulmonary disease in the U.S. Both agents comply with the Montreal Protocol: ipratropium is now available in a metered-dose inhaler without chlorofluorocarbons, and tiotropium is provided as a dry-powder inhaler. On the basis of controlled clinical studies of up to one year's duration, scheduled maintenance therapy with tiotropium, administered once daily, was found to be more effective than ipratropium given four times daily in producing bronchodilation, reducing dyspnea, improving health status, and lowering the frequency of disease exacerbation.

UR - http://www.scopus.com/inward/record.url?scp=34147211271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147211271&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:34147211271

VL - 32

SP - 150

EP - 159

JO - P and T

JF - P and T

SN - 1052-1372

IS - 3

ER -